Trial Profile
Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2021 Results (n=36) of two additional dose levels (dose level 5 (DL 5; n=3), and dose level 6 (DL 6; n=33)) and a subsequent dose expansion cohort has been published in the American Journal of Hematology
- 15 Mar 2021 Status changed from active, no longer recruiting to completed.
- 12 Jun 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.